Peptide Library

Body Protection Compound 157 · PL 14736

A synthetic peptide fragment derived from a gastric protein, studied almost entirely in rodents for soft-tissue and gut healing.

Thymosin Beta-4 (synthetic) · Tβ4

A synthetic version of thymosin β-4, a naturally occurring actin-regulating peptide studied for tissue repair — mostly in animals, with a few early human trials of the parent molecule.

Copper Tripeptide-1 · Copper Peptide

A naturally occurring copper-binding tripeptide with the most direct human data in the Recovery cluster — but almost all of it is topical, cosmetic, and small-scale.

Lysine-Proline-Valine · α-MSH(11–13)

A tiny three–amino-acid tail of the α-MSH hormone studied for anti-inflammatory effects, especially in the gut and skin — preclinical so far.

Tβ4 fragment · Actin-binding domain peptide

The short, actin-binding fragment that most "TB-500" products actually contain — frequently confused with the full thymosin β-4 molecule used in clinical research.

PDA · BPC-157 Arginate

A newer, chemically modified relative of BPC-157 marketed as more stable — but with virtually no published peer-reviewed studies of its own yet.

TH9507 · Egrifta

An FDA-approved GHRH analog with the strongest evidence base in the GH-secretagogue cluster — demonstrated in double-blind RCTs to reduce visceral fat in HIV-associated lipodystrophy.

GHRH(1-29)NH2 · GRF(1-29)

A synthetic analog of the first 29 amino acids of endogenous GHRH — once FDA-approved for pediatric GHD diagnosis and therapy, now available mainly through compounding pharmacies for adult GHD management.

Ibutamoren · Ibutamoren mesylate

The only orally active GH secretagogue with genuine human RCT data — but those trials also revealed worsened insulin sensitivity, a cardiac safety signal in frail elderly, and no effect on Alzheimer disease progression.

NNC 26-0161

A selective, pentapeptide GH secretagogue with a cleaner pituitary-selectivity profile than older GHRP compounds — but characterized almost entirely in animal models, with minimal published human data.

CJC-1295 with DAC · Drug Affinity Complex-GHRH

A long-acting GHRH analog engineered for albumin conjugation — the first GH-secretagogue peptide demonstrated to sustain elevated GH and IGF-1 for over a week in a human pharmacokinetics study.

Growth Hormone Releasing Peptide-2 · KP-102

A synthetic hexapeptide GH secretagogue used clinically in Japan as a diagnostic agent (pralmorelin) — one of the older GHRPs, with more human data than ipamorelin but a less selective side-effect profile.

LY3437943 · triple-G

An investigational triple agonist (GIP / GLP-1 / glucagon) posting the largest phase 2 weight-loss numbers seen so far — but still phase 2, and not approved anywhere.

Ozempic · Wegovy

The GLP-1 agonist that defined the modern weight-loss era — FDA-approved, backed by the large STEP and SUSTAIN trials, and now with cardiovascular-outcome data behind it.

Mounjaro · Zepbound

A dual GIP/GLP-1 agonist, FDA-approved for diabetes and obesity, that beat semaglutide head-to-head on both glucose and weight in a randomized trial.

Saxenda · Victoza

The first-generation daily GLP-1 agonist — well-studied and approved, but now clearly outclassed on weight loss by the weekly drugs that followed it.

AM833 · cagri

An investigational long-acting amylin analog — interesting on its own in phase 2, but its real momentum is as the partner to semaglutide in the CagriSema combination.